BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC

FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]

Children’s Hospital Los Angeles Offers MIBG Therapy for Neuroblastoma

The hospital is one of only a few institutions in the country to allow parents to stay in the same room with their child during the treatment. LOS ANGELES–(BUSINESS WIRE)–Children with high-risk neuroblastoma can now access a specialized, targeted radiation treatment called MIBG therapy at Children’s Hospital Los Angeles—one of the largest neuroblastoma programs in … [Read more…]

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine (CoronaVac) has been approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in children from 3 to 5 years old on 13 July. These children will receive the same dose … [Read more…]

Cloud-based Solutions for Drug Discovery, Development, and Manufacturing – Global Industry Outlook, 2022-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering. The global cloud-based solutions for drug discovery, development, and manufacturing market is expected to register a CAGR of 12.5% during the forecast period of the study. As … [Read more…]

Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally

Ferring’s new family building benefits package for its employees includes financial support and a generous 26-week global minimum standard of paid parental leave for birthing and non-birthing parents No cap on the amount of financial support available on its fertility benefit providers’ services, and accessible to all employees, regardless of their role, location, or specific … [Read more…]

JAIMA and China’s Instrument Information Network to Jointly Host “Japan-China Scientists Forum – Life Sciences”

– Toward disseminating cutting-edge life sciences information on Wednesday, July 20, 2022 – TOKYO–(BUSINESS WIRE)–The Japan Analytical Instruments Manufacturers’ Association (hereinafter “JAIMA”; location: 2-5-16 Kanda Nishiki-cho, Chiyoda-ku, Tokyo, 101-0054 Japan; president: Akira Nakamoto; senior corporate advisor: Shimadzu Corporation) announces that, on Wednesday July 20, 2022, it will jointly hold the second online “Japan-China Scientists Forum … [Read more…]

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

Common Shares Priced at US$9.25 per Share LAVAL, Quebec–(BUSINESS WIRE)–In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with Jefferies, Evercore ISI and … [Read more…]

Express Scripts Sued by AHF Over ‘Claw Backs’

Sweeping federal lawsuit, asserting 14 claims of violations of law in nine U.S. states where AHF operates pharmacies, was filed in federal court in St. Louis, MO AHF asserts Express Scripts, a huge pharmacy benefits manager, manipulates loophole in Medicare “Star Ratings” system as purported justification for “clawing back” millions of dollars of Medicare benefits … [Read more…]

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is providing a bi-weekly default status update in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced via press release dated June 16, 2022 (the “Default Announcement”) that it … [Read more…]